利润表(Fortress Biotech Inc Series A Pfd)
2024年中报 | 2024年一季报 | 2023年年报 | 2023年三季报 | 2023年中报 | 2023年一季报 | 2022年年报 | 2022年三季报 | 2022年中报 | 2022年一季报 | |
---|---|---|---|---|---|---|---|---|---|---|
起始日期 | 2024-01-01 | 2024-01-01 | 2023-01-01 | 2023-01-01 | 2023-01-01 | 2023-01-01 | 2022-01-01 | 2022-01-01 | 2022-01-01 | 2022-01-01 |
截止日期 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 |
报表类型 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 |
报表年结日 | 1231 | 1231 | 1231 | 1231 | 1231 | 1231 | 1231 | 1231 | 1231 | 1231 |
原始币种 | 美元 | 美元 | 美元 | 美元 | 美元 | 美元 | 美元 | 美元 | 美元 | 美元 |
上市前/上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 |
营业收入(元) | 27,926,000.00 | 13,030,000.00 | 84,513,000.00 | 64,567,000.00 | 29,815,000.00 | 12,429,000.00 | 75,743,000.00 | 59,339,000.00 | 42,811,000.00 | 23,925,000.00 |
主营收入(元) | 27,926,000.00 | 13,030,000.00 | 64,994,000.00 | 45,048,000.00 | 29,556,000.00 | 12,381,000.00 | 73,069,000.00 | 56,710,000.00 | 40,255,000.00 | 21,425,000.00 |
其他业务收入(元) | - | - | 19,519,000.00 | 19,519,000.00 | 259,000.00 | 48,000.00 | 2,674,000.00 | 2,629,000.00 | 2,556,000.00 | 2,500,000.00 |
营业成本(元) | 13,357,000.00 | 6,816,000.00 | 26,660,000.00 | 20,645,000.00 | 14,216,000.00 | 6,449,000.00 | 30,775,000.00 | 23,057,000.00 | 15,836,000.00 | 8,203,000.00 |
主营成本(元) | 13,357,000.00 | 6,816,000.00 | 26,660,000.00 | 20,645,000.00 | 14,216,000.00 | 6,449,000.00 | 30,775,000.00 | - | - | 8,203,000.00 |
毛利(元) | 14,569,000.00 | 6,214,000.00 | 57,853,000.00 | 43,922,000.00 | 15,599,000.00 | 5,980,000.00 | 44,968,000.00 | 36,282,000.00 | 26,975,000.00 | 15,722,000.00 |
减:研发费用(元) | 37,495,000.00 | 24,839,000.00 | 106,071,000.00 | 91,995,000.00 | 71,648,000.00 | 39,506,000.00 | 134,876,000.00 | 99,755,000.00 | 69,853,000.00 | 36,722,000.00 |
减:营销费用(元) | 38,777,000.00 | 17,941,000.00 | 94,124,000.00 | 71,512,000.00 | 49,780,000.00 | 25,341,000.00 | 113,656,000.00 | 85,457,000.00 | 55,318,000.00 | 26,270,000.00 |
减:减值及拨备(元) | 2,649,000.00 | - | - | 3,143,000.00 | 3,143,000.00 | - | - | - | - | - |
营业利润(元) | -64,352,000.00 | -36,566,000.00 | -142,342,000.00 | -122,728,000.00 | -108,972,000.00 | -58,867,000.00 | -203,564,000.00 | -148,930,000.00 | -98,196,000.00 | -47,270,000.00 |
加:利息收入(元) | 1,567,000.00 | 833,000.00 | 3,003,000.00 | 2,296,000.00 | 1,751,000.00 | 1,036,000.00 | 1,398,000.00 | 711,000.00 | 292,000.00 | 142,000.00 |
加:利息支出(元) | -4,724,000.00 | -2,602,000.00 | -15,315,000.00 | -13,255,000.00 | -10,721,000.00 | -4,296,000.00 | -13,642,000.00 | -8,897,000.00 | -5,504,000.00 | -2,350,000.00 |
加:权益性投资损益(元) | -597,000.00 | -667,000.00 | - | - | - | - | - | - | - | - |
加:其他收入(支出)(元) | 260,000.00 | -21,000.00 | -3,403,000.00 | -2,049,000.00 | 699,000.00 | 351,000.00 | 1,304,000.00 | - | - | - |
加:公允价值变动损益(元) | - | - | 4,424,000.00 | 10,708,000.00 | 6,166,000.00 | 6,678,000.00 | 1,129,000.00 | - | - | - |
加:汇兑损益(元) | - | - | - | - | - | -47,000.00 | -89,000.00 | -21,000.00 | - | - |
税前利润其他项目(元) | - | - | - | - | -3,369,000.00 | - | - | 669,000.00 | - | - |
持续经营税前利润(元) | -67,846,000.00 | -39,023,000.00 | -153,633,000.00 | -125,028,000.00 | -114,446,000.00 | -55,145,000.00 | -213,464,000.00 | -156,468,000.00 | -103,408,000.00 | -49,478,000.00 |
减:所得税(元) | - | - | 521,000.00 | 142,000.00 | - | - | 449,000.00 | - | - | - |
持续经营净利润(元) | -67,846,000.00 | -39,023,000.00 | -154,154,000.00 | -125,170,000.00 | -114,446,000.00 | -55,145,000.00 | -213,913,000.00 | -156,468,000.00 | -103,408,000.00 | -49,478,000.00 |
净利润(元) | -67,846,000.00 | -39,023,000.00 | -154,154,000.00 | -125,170,000.00 | -114,446,000.00 | -55,145,000.00 | -213,913,000.00 | -156,468,000.00 | -103,408,000.00 | -49,478,000.00 |
减:少数股东损益(元) | -41,481,000.00 | -23,606,000.00 | -93,517,000.00 | -73,812,000.00 | -68,133,000.00 | -33,608,000.00 | -127,338,000.00 | -96,841,000.00 | -66,292,000.00 | -33,718,000.00 |
归属于母公司股东净利润(元) | -26,365,000.00 | -15,417,000.00 | -60,637,000.00 | -51,358,000.00 | -46,313,000.00 | -21,537,000.00 | -86,575,000.00 | -59,627,000.00 | -37,116,000.00 | -15,760,000.00 |
减:归属于优先股净利润及其他项(元) | - | - | 8,032,000.00 | 6,024,000.00 | 4,016,000.00 | - | - | - | - | - |
归属于普通股股东净利润(元) | -31,199,000.00 | -17,731,000.00 | -68,669,000.00 | -57,382,000.00 | -50,329,000.00 | -21,537,000.00 | -86,575,000.00 | -59,627,000.00 | -37,116,000.00 | -15,760,000.00 |
每股收益 | ||||||||||
基本每股收益-普通股(元) | -1.76 | -1.03 | -8.47 | -7.94 | -0.47 | -0.21 | -0.97 | -0.68 | -0.42 | -0.18 |
摊薄每股收益-普通股(元) | -1.76 | -1.03 | -8.47 | -7.94 | -0.47 | -0.21 | -0.97 | -0.68 | -0.42 | -0.18 |
全面收益总额(元) | -67,846,000.00 | - | - | - | - | - | - | - | - | - |
本公司拥有人占全面收益总额(元) | -26,365,000.00 | - | - | - | - | - | - | - | - | - |
非控股权益占全面收益总额(元) | -41,481,000.00 | - | - | - | - | - | - | - | - | - |
公告日期 | 2024-08-13 | 2024-05-15 | 2024-03-28 | 2023-11-14 | 2023-08-14 | 2023-05-15 | 2023-03-31 | 2022-11-14 | 2022-08-11 | 2022-05-12 |
会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 |
审计意见 | ||||||||||
核数师 |